tetano
Editor, Senior Moderator
Hum Vaccin Immunother. 2013 May 31;9(7). [Epub ahead of print]
Influenza vaccines in low and middle income countries: A systematic review of economic evaluations.
Ott JJ, Klein Breteler J, Tam JS, Hutubessy RC, Jit M, de Boer MR.
Source
World Health Organization; Initiative for Vaccine Research; Geneva, Switzerland; Helmholtz Centre for Infection Research; Department of Epidemiology; Braunschweig, Germany.
Abstract
Objectives: Economic evaluations on influenza vaccination from low resource settings are scarce and have not been evaluated using a systematic approach. Our objective was to conduct a systematic review on the value for money of influenza vaccination in low- and middle-income countries. Methods: PubMed and EMBASE were searched for economic evaluations published in any language between 1960 and 2011. Main outcome measures were costs per influenza outcome averted, costs per quality-adjusted life years gained or disability-adjusted life years averted, costs per benefit in monetary units or cost-benefit ratios. Results: Nine economic evaluations on seasonal influenza vaccine met the inclusion criteria. These were model- or randomized-controlled-trial (RCT)-based economic evaluations from middle-income countries. Influenza vaccination provided value for money for elderly, infants, adults and children with high-risk conditions. Vaccination was cost-effective and cost-saving for chronic obstructive pulmonary disease patients and in elderly above 65 y from model-based evaluations, but conclusions from RCTs on elderly varied. Conclusion: Economic evaluations from middle income regions differed in population studied, outcomes and definitions used. Most findings are in line with evidence from high-income countries highlighting that influenza vaccine is likely to provide value for money. However, serious methodological limitations do not allow drawing conclusions on cost-effectiveness of influenza vaccination in middle income countries. Evidence on cost-effectiveness from low-income countries is lacking altogether, and more information is needed from full economic evaluations that are conducted in a standardized manner.
KEYWORDS:
cost analysis, developing countries, economic evaluation, influenza, systematic review, vaccines
PMID:
23732900
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23732900
Influenza vaccines in low and middle income countries: A systematic review of economic evaluations.
Ott JJ, Klein Breteler J, Tam JS, Hutubessy RC, Jit M, de Boer MR.
Source
World Health Organization; Initiative for Vaccine Research; Geneva, Switzerland; Helmholtz Centre for Infection Research; Department of Epidemiology; Braunschweig, Germany.
Abstract
Objectives: Economic evaluations on influenza vaccination from low resource settings are scarce and have not been evaluated using a systematic approach. Our objective was to conduct a systematic review on the value for money of influenza vaccination in low- and middle-income countries. Methods: PubMed and EMBASE were searched for economic evaluations published in any language between 1960 and 2011. Main outcome measures were costs per influenza outcome averted, costs per quality-adjusted life years gained or disability-adjusted life years averted, costs per benefit in monetary units or cost-benefit ratios. Results: Nine economic evaluations on seasonal influenza vaccine met the inclusion criteria. These were model- or randomized-controlled-trial (RCT)-based economic evaluations from middle-income countries. Influenza vaccination provided value for money for elderly, infants, adults and children with high-risk conditions. Vaccination was cost-effective and cost-saving for chronic obstructive pulmonary disease patients and in elderly above 65 y from model-based evaluations, but conclusions from RCTs on elderly varied. Conclusion: Economic evaluations from middle income regions differed in population studied, outcomes and definitions used. Most findings are in line with evidence from high-income countries highlighting that influenza vaccine is likely to provide value for money. However, serious methodological limitations do not allow drawing conclusions on cost-effectiveness of influenza vaccination in middle income countries. Evidence on cost-effectiveness from low-income countries is lacking altogether, and more information is needed from full economic evaluations that are conducted in a standardized manner.
KEYWORDS:
cost analysis, developing countries, economic evaluation, influenza, systematic review, vaccines
PMID:
23732900
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23732900